{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:47:44Z","timestamp":1791658064236,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"IONIS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antisense oligonucleotides (ASOs) are an important therapeutic modality for neurological diseases. Some ASOs cause transient neurobehavioral responses acutely following intrathecal delivery to the central nervous system (CNS). We characterized a subset of these responses, including hypoactivity, spinal reflex loss, paresis, sedation, and ataxia, that are suggestive of neuronal inhibition in rodents and non-human primates. Across species, inhibition-like responses peaked \u223c3 h post-ASO delivery, reversed within 24 h with no sequelae, and could be quantified using simple neurobehavioral scales. Acute inhibition was dose-responsive and was abrogated with lower phosphorothioate and guanine content in ASOs. Acutely inhibitory ASOs transiently disrupted motor pathway neurotransmission\u00a0in vivo and suppressed firing in primary neural cultures. In vitro firing rate suppression of &amp;gt;60% predicted high in vivo acute inhibition scores and was reversed immediately with addition of varying excitatory agents or upon ASO washout. Peak acute inhibition in vivo coincided with peak CNS tissue concentrations of ASO and abated as ASO was internalized by parenchymal cells and cleared from the extracellular space. We propose transient high extracellular concentrations block synaptic transmission via non-specific protein binding of phosphorothioate ASOs. Our results define a comprehensive framework for quantifying and mitigating ASO-mediated acute inhibition.<\/jats:p>","DOI":"10.1093\/nar\/gkaf1333","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:13:01Z","timestamp":1763125981000},"source":"Crossref","is-referenced-by-count":10,"title":["Acute neuronal inhibition response caused by phosphorothioate antisense oligonucleotides following local delivery to the central nervous system"],"prefix":"10.1093","volume":"54","author":[{"given":"Jacqueline G","family":"O\u2019Rourke","sequence":"first","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Mazur","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Platoshyn","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine, Department of Anesthesiology , La Jolla, CA 92093 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bravo\u00a0Hernandez","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K","family":"Klein","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Burel","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hoffmaster","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zanardi","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paymaan","family":"Jafar-nejad","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Marsala","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine, Department of Anesthesiology , La Jolla, CA 92093 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P","family":"Henry","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E","family":"Swayze","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Powers","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0945-0769","authenticated-orcid":false,"given":"Holly B","family":"Kordasiewicz","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Neurology Research , Carlsbad, CA 92008 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026020306000438800_B1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"key":"2026020306000438800_B2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020306000438800_B3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"2026020306000438800_B4","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of tofersen treatment in patients with SOD1-ALS in a \u201creal-world\u201d setting \u2013 a 12-month multicenter cohort study from the German early access program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026020306000438800_B5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"2026020306000438800_B6","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.neuron.2023.05.027","article-title":"Antisense drugs for rare and ultra-rare genetic neurological diseases","volume":"111","author":"McCauley","year":"2023","journal-title":"Neuron"},{"key":"2026020306000438800_B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/nat.2022.0060","article-title":"Consensus guidelines for the design and in vitro preclinical efficacy testing N-of-1 exon skipping antisense oligonucleotides","volume":"33","author":"Aartsma-Rus","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"2026020306000438800_B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.molmed.2021.12.002","article-title":"Meeting the needs of patients with ultrarare diseases","volume":"28","author":"Crooke","year":"2022","journal-title":"Trends Mol Med"},{"key":"2026020306000438800_B9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"2026020306000438800_B10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"2026020306000438800_B11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-nejad","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026020306000438800_B12","doi-asserted-by":"publisher","first-page":"e129240","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"2026020306000438800_B13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0014-5793(01)03248-3","article-title":"Non-antisense cellular responses to oligonucleotides","volume":"510","author":"Anselmet","year":"2002","journal-title":"FEBS Lett"},{"key":"2026020306000438800_B14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/nar\/gky1260","article-title":"Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay","volume":"47","author":"Gaus","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026020306000438800_B15","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide\u2013protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026020306000438800_B16","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1021\/bi002396x","article-title":"Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism","volume":"40","author":"Sheehan","year":"2001","journal-title":"Biochemistry"},{"key":"2026020306000438800_B17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","article-title":"Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route","volume":"31","author":"Jia","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026020306000438800_B18","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.omtn.2024.102359","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation","volume":"35","author":"Miller","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026020306000438800_B19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/nat.2021.0071","article-title":"Acute neurotoxicity of antisense oligonucleotides after intracerebroventricular injection into mouse brain can be predicted from sequence features","volume":"32","author":"Hagedorn","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"2026020306000438800_B20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1091581820948454","article-title":"Range of neurological signs in cynomolgus monkeys after intrathecal bolus administration of antisense oligonucleotides","volume":"39","author":"Korte","year":"2020","journal-title":"Int J Toxicol"},{"key":"2026020306000438800_B21","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1016\/j.ymthe.2024.10.024","article-title":"Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system","volume":"32","author":"Moazami","year":"2024","journal-title":"Mol Ther"},{"key":"2026020306000438800_B22","article-title":"Transient acute neuronal activation response caused by high concentrations of oligonucleotides in the cerebral spinal fluid","author":"Bravo\u00a0Hernandez","journal-title":"Nucleic Acids Res"},{"key":"2026020306000438800_B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jneumeth.2017.02.001","article-title":"Development of a simple, rapid, and robust intrathecal catheterization method in the rat","volume":"280","author":"Mazur","year":"2017","journal-title":"J Neurosci Methods"},{"key":"2026020306000438800_B24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat Med"},{"key":"2026020306000438800_B25","doi-asserted-by":"publisher","first-page":"E736","DOI":"10.1073\/pnas.1222809110","article-title":"ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43","volume":"110","author":"Arnold","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020306000438800_B26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1006\/jsre.1993.1103","article-title":"Panmyelic epidural cooling protects against ischemic spinal cord damage","volume":"55","author":"Marsala","year":"1993","journal-title":"J Surg Res"},{"key":"2026020306000438800_B27","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ymthe.2022.04.023","article-title":"Precision spinal gene delivery-induced functional switch in nociceptive neurons reverses neuropathic pain","volume":"30","author":"Tadokoro","year":"2022","journal-title":"Mol Ther"},{"key":"2026020306000438800_B28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"2026020306000438800_B29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/BF02246955","article-title":"Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice","volume":"110","author":"Nevins","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"2026020306000438800_B30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0149-7634(01)00011-2","article-title":"A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field","volume":"25","author":"Choleris","year":"2001","journal-title":"Neurosci Biobehav Rev"},{"key":"2026020306000438800_B31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"2026020306000438800_B32","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/cbdv.201100081","article-title":"An overview of sugar-modified oligonucleotides for antisense therapeutics","volume":"8","author":"Prakash","year":"2011","journal-title":"Chem Biodivers"},{"key":"2026020306000438800_B33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.neuro.2010.04.001","article-title":"Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century","volume":"31","author":"Johnstone","year":"2010","journal-title":"Neurotoxicology"},{"key":"2026020306000438800_B34","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1039\/c2cc32286b","article-title":"Structure and nuclease resistance of 2\u2032,4\u2032-constrained 2\u2032-O-methoxyethyl (cMOE) and 2\u2032-O-ethyl (cEt) modified DNAs","volume":"48","author":"Pallan","year":"2012","journal-title":"Chem Commun"},{"key":"2026020306000438800_B35","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.1016\/S0040-4039(97)10322-7","article-title":"Synthesis of 2\u2032-O,4\u2032-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering","volume":"38","author":"Obika","year":"1997","journal-title":"Tetrahedron Lett"},{"key":"2026020306000438800_B36","volume-title":"Spinal drug delivery","author":"Yaksh","year":"1999.","edition":"1st ed."},{"key":"2026020306000438800_B37","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1007\/s10439-011-0319-0","article-title":"Measurement of synchronous activity by microelectrode arrays uncovers differential effects of sublethal and lethal glutamate concentrations on cortical neurons","volume":"39","author":"Kutzing","year":"2011","journal-title":"Ann Biomed Eng"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/3\/gkaf1333\/66285268\/gkaf1333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/3\/gkaf1333\/66285268\/gkaf1333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:00:06Z","timestamp":1770116406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkaf1333\/8415850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaf1333","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,1,6]]},"article-number":"gkaf1333"}}